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ABSTRACT 
Ischemic heart disease and stroke are the two leading causes of death worldwide. Antiplatelet 
therapy plays the most significant role in the management of these cardiovascular and 
cerebrovascular occlusive events to prevent recurrent ischemic attack. Clopidogrel, an 
antiplatelet drug, is widely prescribed either alone or in combination with aspirin as dual 
antiplatelet therapy for the prevention of vascular occlusive events. The antiplatelet response 
to clopidogrel varies widely. Hyporesponders and nonresponders are likely to have adverse 
cardiovascular events during follow-up. Some drugs, such as proton pump inhibitors 
(omeprazole), calcium channel blockers, selective serotonin reuptake inhibitors (nefazadone), 
coumarin derivatives (phenprocoumon), benzodiazepines, sulfonylurea, erythromycin, and 
itraconazole, decrease the antiplatelet effect of clopidogrel when administered concomitantly. 
Decreased response to clopidogrel is common among Asians due to genetic polymorphisms 
associated with clopidogrel resistance, and it is nearly 70% in some of the Asian 
communities. It is necessary to study Asian populations, because there are a large number of 
Asians throughout the world due to increased migration. Current guidelines do not make 
genetic testing or platelet response testing mandatory prior to clopidogrel prescription. 
Therefore, it is important for clinicians treating Asian patients to keep in mind the 
interindividual variability in response to clopidogrel when prescribing the drug. 
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